Prevacid Decline Is Weak Spot In Otherwise Strong Quarter For Abbott

Abbott posts robust 14% sales growth for the quarter driven by strong Humira performance, but acknowledges that Prevacid sales will be down as much as 10% for full year. The company believes, however, that the upside from Humira outweighs any downside from the performance of the TAP joint venture.